Sector News

PhRMA throws controversy-ridden Valeant under the bus

October 23, 2015
Life sciences

Pharma industry trade group PhRMA generally protects its own amid controversy. But now, it’s put up a statement on its website criticizing a drugmaker that’s surrounded by plenty.

Thursday, the group likened the Canadian drugmaker Valeant Pharmaceuticals to much-maligned Turing Pharmaceuticals, noting that its strategy is “more reflective of a hedge fund than an innovative biopharmaceutical company.”

Unlike Valeant, the innovators “have R&D at the core–and the numbers to prove it,” the post says. The Quebec-based pharma, on the other hand, has made its way by serially acquiring companies and squeezing out costs, investing on average less than 3% of its total revenue on R&D.

It’s the latest effort by the group to distance itself from the drug price uproar coming from lawmakers, presidential candidates and–in the case of Valeant–federal prosecutors. Earlier this week, short seller Citron Research likened Valeant to Enron and claimed it used its relationship with specialty pharmacies to inflate its top line; that relationship was one of the subjects of a pair of federal subpoenas the company last week announced it had received.

Turing, which drew ire when it last month hiked the price of Daraprim by more than 5000%, felt a similar burn from the trade organization when PhRMA put out a tweet stating that the company didn’t represent the values of its member companies.

Meanwhile, Valeant said Monday that it’s looking to sock more money into R&D. It’ll also look to hive off its neurology and “other drugs” unit, which has been subject to some of its biggest price hikes, and it’ll pursue fewer–if any–transactions “focused on mispriced products,” CEO J. Michael Pearson said on a conference call.

But those assurances didn’t do much to sooth investors’ worries when Citron’s “phantom sales” allegations hit. After plunging 19% Wednesday, Valeant’s share price dropped another 7.4%, Bloomberg points out, with one BMO Capital Markets analyst downgrading the stock.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach